Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of
rheumatic diseases since their incorporation into treatment protocols two decades ago …

At first sight the bleeding disorder hemophilia A seems to have little in common with immune
disorders, but immunology research intersects with other disciplines including hematology …

Expansion of human regulatory T cells (Tregs) for clinical applications offers great promise
for the treatment of undesirable immune responses in autoimmunity, transplantation, allergy …

Inhibitory antibodies to factor VIII (FVIII) are a major complication in the treatment of
hemophilia A, affecting approximately 20% to 30% of patients. Current treatment for …

A major complication of hemophilia A therapy is the development of alloantibodies
(inhibitors) that neutralize intravenously administered coagulation factor VIII (FVIII). Immune …

The pathogenesis of inhibitory antibodies has been the focus of major scientific interest over
the last decades, and several studies on underlying immune mechanisms and risk factors for …

Development of neutralizing antibodies against biotherapeutic agents administered to
prevent or treat various clinical conditions is a longstanding and growing problem faced by …

The purpose of this narrative review was to provide an overview that allows readers to
improve their understanding of hemophilia A, which is considered a genetic disease with a …

Development of inhibitory antibodies to infused factor VIII (FVIII) concentrates continues to
be the most serious complication of haemophilia A management. Induction of immune …

Formation of pathogenic antibodies is a major problem in replacement therapies for
inherited protein deficiencies. For example, antibodies to coagulation factors ('inhibitors') …